Lung Microbiome and Inflammation in Early COPD

Description

This is a cross sectional case controlled study to assess lung microbiome and inflammation in smokers with and without Chronic Obstructive Pulmonary Disease (COPD). Investigators will look at active bacterial metabolic pathways in the lower airways using metagenomic and metabolomic approaches an assess relationships among microbiome, metagenome, metabolome and host immune responses in COPD and controls. Investigators believe COPD cases will have higher prevalence of pneumotype supraglottic predominant taxa (SPT) than matched controls.

Conditions

Chronic Obstuctive Pulmonary Disease

Study Overview

Study Details

Study overview

This is a cross sectional case controlled study to assess lung microbiome and inflammation in smokers with and without Chronic Obstructive Pulmonary Disease (COPD). Investigators will look at active bacterial metabolic pathways in the lower airways using metagenomic and metabolomic approaches an assess relationships among microbiome, metagenome, metabolome and host immune responses in COPD and controls. Investigators believe COPD cases will have higher prevalence of pneumotype supraglottic predominant taxa (SPT) than matched controls.

Lung Microbiome and Inflammation in Early Chronic Obstructive Pulmonary Disease (COPD)

Lung Microbiome and Inflammation in Early COPD

Condition
Chronic Obstuctive Pulmonary Disease
Intervention / Treatment

-

Contacts and Locations

New York

New York University School of Medicine, New York, New York, United States, 10016

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Case definition: Smokers (\>20 pack-year) with airflow obstruction (FEV1/FVC\<70) and FEV1\>50% predicted (early COPD GOLD 1 or 2)
  • * Control definition: Smokers with normal spirometry will serve as controls.
  • * FEV1 \< 50% NOT 70
  • * Significant cardiovascular disease defined as abnormal EKG, known or suspected coronary artery disease or congestive heart failure.
  • * Diabetes mellitus
  • * Significant liver or renal disease
  • * Severe coagulopathy (INR \> 1.4, PTT \> 40 seconds and platelet count \< 150x103 cells).
  • * Pregnancy
  • * ETOH use of more than \>6 beers or \>4 mixed drinks daily
  • * Lack of capacity to provide informed consent.
  • * Antibiotic use within the prior 2months

Ages Eligible for Study

18 Years to 70 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

NYU Langone Health,

Leopoldo Segal, MD, PRINCIPAL_INVESTIGATOR, New York University Medical School

Study Record Dates

2026-08